AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis

EMBO Journal

Volumn 31, Issue 20, 2012, Pages 3961-3975

  Höpker, Katja ^a   Hagmann, Henning ^a   Khurshid, Safiya ^a   Chen, Shuhua ^a,b   Hasskamp, Pia ^a   Seeger Nukpezah, Tamina ^a   Schilberg, Katharina ^a   Heukamp, Lukas ^a   Lamkemeyer, Tobias ^a   Sos, Martin L ^c   Thomas, Roman K ^a,c   Lowery, Drew ^d   Roels, Frederik ^e   Fischer, Matthias ^a,e   Liebau, Max C ^e   Resch, Ulrike ^a   Kisner, Tülay ^a   Röther, Fabian ^a   Bartram, Malte P ^a   Müller, Roman Ulrich ^a   Fabretti, Francesca ^a   Kurschat, Peter ^c   Schumacher, Björn ^a   Gaestel, Matthias ^f   Medema, René H ^g   Yaffe, Michael B ^d   Schermer, Bernhard ^a,c   Reinhardt, H Christian ^a,b   Benzing, Thomas ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

AATF; apoptosis; checkpoint; DNA damage; kinase signalling; MK2; p53

Indexed keywords

APOPTOSIS ANTAGONIZING TRANSCRIPTION FACTOR; CISPLATIN; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NOCODAZOLE; PROTEIN BAK; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DNA DAMAGE; ENDOMETRIUM CANCER; G2 PHASE CELL CYCLE CHECKPOINT; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; GENE REPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HEK293 CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; MYOSIN LIGHT CHAINS; NEUROBLASTOMA; OSMOTIC PRESSURE; PHOSPHORYLATION; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84867574821     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2012.236     Document Type: Article

References (37)

1. Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400-414
2. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S (1999) Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 18: 1223-1234
3. Bruno T, De Angelis R, De Nicola F, Barbato C, Di Padova M, Corbi N, Libri V, Benassi B, Mattei E, Chersi A, Soddu S, Floridi A, Passananti C, Fanciulli M (2002) Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb. Cancer Cell 2: 387-399
4. Bruno T, De Nicola F, Iezzi S, Lecis D, D'Angelo C, Di Padova M, Corbi N, Dimiziani L, Zannini L, Jekimovs C, Scarsella M, Porrello A, Chersi A, Crescenzi M, Leonetti C, Khanna KK, Soddu S, Floridi A, Passananti C, Delia D et al (2006) Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell 10: 473-486
5. Bruno T, Iezzi S, De Nicola F, Di Padova M, Desantis A, Scarsella M, Di Certo MG, Leonetti C, Floridi A, Passananti C, Fanciulli M (2008) Che-1 activates XIAP expression in response to DNA damage. Cell Death Differ 15: 515-520
6. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace Jr. AJ (2001) Initiation of a G2/ M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411: 102-107
7. Das S, Raj L, Zhao B, Kimura Y, Bernstein A, Aaronson SA, Lee SW (2007) Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation. Cell 130: 624-637
8. Di Certo MG, Corbi N, Bruno T, Iezzi S, De Nicola F, Desantis A, Ciotti MT, Mattei E, Floridi A, Fanciulli M, Passananti C (2007) NRAGE associates with the anti-apoptotic factor Che-1 and regulates its degradation to induce cell death. J Cell Sci 120(Pt 11): 1852-1858
9. Elia AE, Cantley LC, Yaffe MB (2003) Proteomic screen finds pSer/ pThr-binding domain localizing Plk1 to mitotic substrates. Science 299: 1228-1231
10. Engel K, Kotlyarov A, Gaestel M (1998) Leptomycin B-sensitive nuclear export of MAPKAP kinase 2 is regulated by phosphorylation. EMBO J 17: 3363-3371
11. Espinosa JM (2008) Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27: 4013-4023
12. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
13. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078
14. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-1909
15. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S (2010) Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 120: 3594-3605
16. Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869
17. Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950
18. Manke IA, Lowery DM, Nguyen A, Yaffe MB (2003) BRCTrepeats as phosphopeptide-binding modules involved in protein targeting. Science 302: 636-639
19. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17: 37-48
20. Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369: 2106-2120
21. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805
22. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694
23. Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: Proteomewide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 3635-3641
24. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N (2000a) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288: 1053-1058
25. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y (2000b) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862
26. Raman M, Earnest S, Zhang K, Zhao Y, Cobb MH (2007) TAO kinases mediate activation of p38 in response to DNA damage. EMBO J 26: 2005-2014
27. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11: 175-189
28. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MATM,Wang X, Linding R, Ong S-E,Weaver D, Carr SA, Yaffe MB (2010) DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell 40: 34-49
29. Reinhardt HC, Schumacher B (2012) The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 28: 128-136
30. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, Telliez JB (2007) The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 27: 170-181
31. Selvakumaran M, Lin HK, Miyashita T,Wang HG, Krajewski S, Reed JC, Hoffman B, Liebermann D (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: a paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798
32. Seoane J, Le HV, Massague J (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734
33. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909-923
34. Watanabe T, Hosoya H, Yonemura S (2007) Regulation of myosin II dynamics by phosphorylation and dephosphorylation of its light chain in epithelial cells. Mol Biol Cell 18: 605-616
35. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q et al (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124: 207-219
36. Yang Y, Gourinath S, Kovacs M, Nyitray L, Reutzel R, Himmel DM, O'Neall-Hennessey E, Reshetnikova L, Szent-Gyorgyi AG, Brown JH, Cohen C (2007) Rigor-like structures from muscle myosins reveal key mechanical elements in the transduction pathways of this allosteric motor. Structure 15: 553-564
37. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace Jr. AJ (1994) Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751